December 9, 2016 — Bristol-Myers Squibb has agreed to pay a $19.5 million settlement with 43 states for marketing the anti-psychotic drug Abilify for unapproved uses.
The settlement places strict rules on how the drug-maker can promote Abilify moving forward, and will prohibit:
- Promotion for “off-label” uses not approved by the FDA
- Using medical grants to promote the drug
- Paying doctors for promotional activities without disclosing their connections
- Making unsubstantiated claims of superiority or effectiveness
Investigators concluded that the drug-maker illegally marketed Abilify for children. The label now warns that Abilify “may increase suicidal thoughts or behaviors in some children, teenagers, and young adults, especially within the first few months of treatment or when the dose is changed.”
The company was accused of marketing Abilify to elderly people with dementia and Alzheimer’s disease. Since 2006, Abilify has carried a “Black Box” warning against its use in patients with dementia-related psychosis due to the risk of death.
Antipsychotics are improperly used in some nursing homes to “chemically restrain” hard-to-handle patients. They also double the patient’s risk of stroke and death.
Do I have an Abilify Lawsuit?
The Schmidt Firm, PLLC is currently accepting Abilify induced injury cases in all 50 states. If you or somebody you know became addicted to gambling, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.